A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer.
Adult
Biomarkers, Tumor
/ blood
Blood Cell Count
/ statistics & numerical data
Blood Platelets
/ metabolism
Breast Neoplasms
/ blood
Female
Humans
Inflammatory Breast Neoplasms
/ blood
Kaplan-Meier Estimate
Lymphocytes
/ metabolism
Middle Aged
Neutrophils
/ metabolism
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Retrospective Studies
Immune response
Inflammatory breast cancer (IBC)
Lymphocyte-monocyte ratio (LMR)
Neutrophil-to-lymphocyte ratio (NLR)
Platelet-lymphocyte ratio (PLR)
Stromal tumor infiltrating lymphocytes (sTIL)
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
17
03
2020
revised:
05
07
2020
accepted:
10
08
2020
pubmed:
6
9
2020
medline:
30
6
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Inflammatory breast cancer (IBC) is an uncommon, but aggressive form of breast cancer that accounts for a disproportionally high fraction of breast cancer related mortality. The aim of this study was to explore the peripheral immune response and the prognostic value of blood-based biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), in a large IBC cohort. We retrospectively identified 127 IBC patients and collected lab results from in-hospital medical records. The differential count of leukocytes was determined at the moment of diagnosis, before any therapeutic intervention. A cohort of early stage (n = 108), locally advanced (n = 74) and metastatic breast cancer patients (n = 41) served as a control population. The NLR was significantly higher in IBC compared to an early stage breast cancer cohort, but no difference between IBC patients and locally advanced breast cancer patients was noted. In the metastatic setting, there was also no significant difference between IBC and nIBC. However, a high NLR (>4.0) remained a significant predictor of worse outcome in IBC patients (HR: 0.49; 95% CI: 0.24-1.00; P = .05) and a lower platelet-lymphocyte ratio (PLR) (≤210) correlated with a better disease-free survival (DFS) (HR: 0.51; 95% CI: 0.28-0.93; P = .03). Patients with a high NLR (>4.0) have a worse overall prognosis in IBC, while the PLR correlated with relapse free survival (RFS). Since NLR and PLR were not specifically associated with IBC disease, they can be seen as markers of more extensive disease.
Identifiants
pubmed: 32890963
pii: S0960-9776(20)30159-4
doi: 10.1016/j.breast.2020.08.006
pmc: PMC7481565
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212-220Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
J Cancer. 2016 Jun 03;7(9):1095-104
pubmed: 27326253
Oncotarget. 2017 May 30;8(22):35656-35668
pubmed: 27374101
Lancet Oncol. 2015 Nov;16(15):e568-e576
pubmed: 26545845
Lancet Oncol. 2017 Apr;18(4):e228-e232
pubmed: 28368261
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Cancer Biol Ther. 2020;21(2):189-196
pubmed: 31684807
PLoS One. 2014 Nov 05;9(11):e111886
pubmed: 25372468
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Nat Rev Cancer. 2018 Aug;18(8):485-499
pubmed: 29703913
Oncol Lett. 2019 Dec;18(6):6275-6283
pubmed: 31788105
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Clin Transl Oncol. 2018 Dec;20(12):1548-1556
pubmed: 29766456
Int J Clin Oncol. 2015 Feb;20(1):70-81
pubmed: 24532163
Semin Oncol. 2008 Feb;35(1):11-6
pubmed: 18308141
Oncotarget. 2015 May 30;6(15):13506-19
pubmed: 25940795
PLoS One. 2018 Jul 26;13(7):e0200936
pubmed: 30048474
Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065
pubmed: 31452692
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
Breast Cancer Res Treat. 2019 Apr;174(2):443-452
pubmed: 30604000
J Breast Cancer. 2019 Sep 18;22(3):425-438
pubmed: 31598342
Sci Rep. 2019 Nov 18;9(1):16979
pubmed: 31740715
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Cancer Med. 2019 Aug;8(9):4135-4148
pubmed: 31197958
Breast Cancer Res. 2019 Feb 18;21(1):28
pubmed: 30777104
Clin Cancer Res. 2013 Sep 1;19(17):4685-96
pubmed: 23396049
J Breast Cancer. 2013 Mar;16(1):55-9
pubmed: 23593082
Breast. 2019 Apr;44:33-38
pubmed: 30611095
PLoS One. 2018 Nov 14;13(11):e0207224
pubmed: 30427884
Clin Breast Cancer. 2020 Aug;20(4):307-316.e1
pubmed: 32305297
Ann Oncol. 2011 Mar;22(3):515-523
pubmed: 20603440
Br J Cancer. 2015 Jun 30;113(1):150-8
pubmed: 26022929
Sci Rep. 2020 Apr 24;10(1):7010
pubmed: 32332763
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Breast Cancer Res Treat. 2020 Apr;180(2):385-395
pubmed: 32043194
BMC Cancer. 2015 Mar 28;15:195
pubmed: 25884918
Immunol Cell Biol. 2018 Jan;96(1):114-120
pubmed: 29359459
Oncotarget. 2017 Jan 3;8(1):1023-1030
pubmed: 27906679
Breast. 2020 Apr;50:141-148
pubmed: 31607527
Cancer Biomark. 2014;14(5):303-12
pubmed: 25171472
PLoS One. 2018 Apr 6;13(4):e0195042
pubmed: 29624591
Ann Surg Oncol. 2016 Apr;23(4):1104-10
pubmed: 26511266